{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:55:12Z","timestamp":1793656512765,"version":"4.5.1"},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:p>This cohort study examines the role of comprehensive bridging radiotherapy in the setting of chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.<\/jats:p>","DOI":"10.1001\/jamaoncol.2024.1113","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T15:00:51Z","timestamp":1715266851000},"page":"979","source":"Crossref","is-referenced-by-count":18,"title":["Comprehensive Bridging Radiotherapy for Limited Pre-CART Non-Hodgkin Lymphoma"],"prefix":"10.1001","volume":"10","author":[{"given":"Omran","family":"Saifi","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic Jacksonville, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Breen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic Rochester, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Rule","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic Phoenix, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota"},{"name":"Division of Experimental Pathology, Mayo Clinic Rochester, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Munoz","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic Phoenix, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic Jacksonville, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic Jacksonville, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"19","key":"cld240006r1","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"cld240006r2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.radonc.2021.11.031","article-title":"Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?","volume":"166","author":"Saifi","year":"2022","journal-title":"Radiother Oncol"},{"issue":"5","key":"cld240006r3","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.ijrobp.2021.06.038","article-title":"Patterns and predictors of failure in recurrent or refractory large B-cell lymphomas after chimeric antigen receptor T-cell therapy.","volume":"111","author":"Figura","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"cld240006r4","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.ijrobp.2022.07.492","article-title":"Don\u2019t put the CART before the horse: the role of radiation therapy in peri-CAR T-cell therapy for aggressive B-cell non-Hodgkin lymphoma.","volume":"116","author":"Saifi","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"13","key":"cld240006r5","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma.","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"key":"cld240006r6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.radonc.2022.10.018","article-title":"Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed\/refractory aggressive B-cell lymphoma.","volume":"177","author":"Yu","year":"2022","journal-title":"Radiother Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2818571\/jamaoncology_saifi_2024_ld_240006_1720732650.41872.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T15:04:54Z","timestamp":1721315094000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2818571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":6,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.1113","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,1]]}}}